HIG Capital Sells Celerion Holdings to THL Partners Affiliates for $1.8B

Why It Matters

The sale proves that mature healthcare‑service assets can still command premium valuations, bolstering returns for private‑equity investors in a still‑uneven M&A climate.

Key Takeaways

• HIG sold Celerion for $1.8 billion to THL Partners affiliates.
• Exit adds to >$4.5 billion in deals since late 2025.
• Celeron’s global CRO platform spans North America, Europe, Asia.
• HIG’s Advantage strategy targets scale and transformation in mid‑market firms.
• Private‑equity exit activity rebounds, especially in resilient healthcare services.

Pulse Analysis

HIG Capital’s recent divestiture of Celerion underscores the firm’s disciplined Advantage strategy, which focuses on scaling mid‑market businesses through active management and targeted transformations. By shepherding Celerion—a global contract research organization that supports first‑in‑human and proof‑of‑concept studies—into a $1.8 billion exit, HIG demonstrates its ability to extract value from complex, science‑driven assets while maintaining a diversified portfolio that spans buyouts, credit, real estate, and infrastructure.

The CRO market has become a magnet for private‑equity capital due to its steady demand from pharmaceutical and biotech firms seeking to de‑risk early development phases. Celerion’s footprint across three continents provides a competitive edge, allowing sponsors to run trials efficiently and accelerate timelines. The transaction’s timing aligns with a broader resurgence in healthcare services exits, as investors view the sector as recession‑resilient and capable of delivering consistent cash flows, even when broader dealmaking slows.

Looking ahead, the successful Celerion exit may encourage other PE firms to pursue similar opportunities in niche, high‑growth segments of the life‑science ecosystem. As capital returns become a priority, managers are likely to accelerate distributions, leveraging improved sentiment in the M&A market to secure attractive multiples. This trend could catalyze a wave of strategic sales, reinforcing the narrative that private‑equity can generate meaningful liquidity while supporting the continued innovation pipeline in drug development.

Deal Summary

HIG Capital completed the sale of clinical research organization Celerion Holdings to funds affiliated with THL Partners in a $1.8 billion transaction. The deal adds to HIG’s Advantage strategy exits, which have totaled over $4.5 billion since late 2025. The transaction highlights growing M&A activity in the healthcare services sector.